Is There Still Room to Profit From Biogen?
For decades, every tale in the world of Alzheimer's drug development has followed the same story arc: first a period of hope, expensive effort, and no small amount of brilliance. Then, a series of clinical trials that reveals that the candidate treatment isn't effective against the disease. So it seemed to be this spring for Biogen's (NASDAQ: BIIB) aducanumab. The company ended its trial of the drug because it didn't seem to work. But last week, it revealed positive new data, and said it would ask for FDA approval of aducanumab, which put a rocket under its stock price. In this segment of the Oct. 25 Motley Fool Money podcast, host Chris Hill and senior analyst Ron Gross consider just how extraordinary this turn of events is, and offer up an opinion on the obvious question for investors: Is it too late to buy in to Biogen?
To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. To get started investing, check out our quick-start guide to investing in stocks. A full transcript follows the video.
Source Fool.com
